MD Anderson and Amgen to accelerate early-stage treatments for several cancer types – EurekAlert (press release)
|
MD Anderson and Amgen to accelerate early-stage treatments for several cancer types
EurekAlert (press release) The collaborations will focus on Amgen’s bispecific T cell engager (BiTE®), chimeric antigen receptor (CAR) T cell and small molecule programs. Amgen is advancing both types of T cell therapies against different targets and, in some cases, the same target. |
Genetic Engineering & Biotechnology News |
Supplement: CRISPR in the Courthouse
Genetic Engineering & Biotechnology News In this interview, Professor Sherkow provides a brief accessible history of the ongoing CRISPR patent dispute, and he discusses this dispute’s implications as well as other legal issues impacting biotechnology. (This is an edited version of the … |